IEX IDEX Corporation
High-quality niche compounder, but at 30x earnings the market already pays for full recovery.
The story
IDEX is a portfolio of niche, engineered flow-control, precision-instrument and fire/safety businesses that sell mission-critical, specified-in components with high switching costs and strong aftermarket pull. It is a mature serial acquirer: organic growth tracks industrial GDP plus pricing, and M&A adds a few points a year. Recent margin compression reflects the industrial destocking cycle and acquisition amortization, not a broken franchise. Revenue is now re-accelerating as its life-science and semiconductor exposure recovers.
TTM revenue is up about 6% and the margin is 20.9%. I set margins to recover toward 24%, roughly the 2021-2022 level and IDEX's long-run adjusted economics, rather than staying at the trough. Reported sales-to-capital of 0.63 is weighed down by goodwill from past acquisitions, so I use a marginal 1.6 that blends capital-light organic growth with ongoing bolt-on deals. The 10-year horizon fits a durable niche moat, but the moat is not wide enough to justify 15 years.
Value drivers
| Revenue growth (Y1) | 6.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 24.0% |
| Years to target margin | 4 |
| Sales-to-capital | 1.60 |
| Beta | 1.00 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 9.2% |
| Terminal WACC | 9.2% |
Valuation bridge
| PV of explicit FCFF | 4.50B |
| PV of terminal value | 5.23B |
| Equity value | 8.41B |
| ÷ shares → per share | $114.54 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 3.88B | 6.0% | 21.7% | 642.06M | 137.19M | 504.87M | 462.41M |
| 2 | 4.10B | 5.7% | 22.5% | 702.69M | 138.69M | 564.00M | 473.13M |
| 3 | 4.32B | 5.4% | 23.2% | 766.14M | 139.50M | 626.63M | 481.45M |
| 4 | 4.55B | 5.2% | 24.0% | 832.21M | 139.59M | 692.62M | 487.40M |
| 5 | 4.77B | 4.9% | 24.0% | 872.90M | 138.91M | 733.98M | 473.07M |
| 6 | 4.99B | 4.6% | 24.0% | 913.15M | 137.43M | 775.72M | 457.92M |
| 7 | 5.20B | 4.3% | 24.0% | 952.72M | 135.10M | 817.61M | 442.06M |
| 8 | 5.42B | 4.1% | 24.0% | 991.35M | 131.92M | 859.43M | 425.59M |
| 9 | 5.62B | 3.8% | 24.0% | 1.03B | 127.87M | 900.94M | 408.62M |
| 10 | 5.82B | 3.5% | 24.0% | 1.06B | 122.94M | 941.87M | 391.26M |
Key risks
- Prolonged industrial or semiconductor capex slump keeps volumes and margins depressed
- Overpaying for acquisitions (as in recent Health & Science deals) erodes returns on capital
- Valuation already prices in a full margin recovery, leaving little room for execution misses
Catalysts
- Margin recovery back above 23% as volumes return and 80/20 programs take hold
- Life-science and semiconductor end-market rebound lifting organic growth to mid-single digits